We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+2.42%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$940M
AUM Growth
-$233M
Cap. Flow
-$192M
Cap. Flow %
-20.48%
Top 10 Hldgs %
46.78%
Holding
113
New
30
Increased
18
Reduced
25
Closed
32

Top Buys

Rank Stock Value
1
NVS icon
Novartis
NVS
+$26.6M
2
ELV icon
Elevance Health
ELV
+$26.1M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$16.4M
4
BAX icon
Baxter International
BAX
+$16.3M
5
RDNT icon
RadNet
RDNT
+$14.8M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$30.3M
2
CAH icon
Cardinal Health
CAH
+$29.6M
3
LLY icon
Eli Lilly
LLY
+$29.3M
4
ISRG icon
Intuitive Surgical
ISRG
+$20.9M
5
MRK icon
Merck
MRK
+$19.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
26
Krystal Biotech
KRYS
$9.68B
$10.8M 1.15%
60,000
+5,000
+9% +$841K
INSP icon
27
Inspire Medical Systems
INSP
$1.71B
$10.4M 1.1%
65,000
-35,000
-35% -$6.33M
TARS icon
28
Tarsus Pharmaceuticals
TARS
$3.05B
$10.3M 1.09%
200,000
-150,000
-43% -$7.41M
PEN icon
29
Penumbra
PEN
$12.9B
$9.36M 1%
+35,000
New +$9.47M
EW icon
30
Edwards Lifesciences
EW
$54B
$9.06M 0.96%
+125,000
New +$8.95M
RVMD icon
31
Revolution Medicines
RVMD
$44.1B
$8.84M 0.94%
250,000
-300,000
-55% -$12.2M
MCK icon
32
McKesson
MCK
$105B
$8.08M 0.86%
12,000
-23,000
-66% -$14.2M
MLTX icon
33
MoonLake Immunotherapeutics
MLTX
$1.41B
$7.81M 0.83%
200,000
– –
TEVA icon
34
Teva Pharmaceuticals
TEVA
$42.5B
$7.68M 0.82%
500,000
– –
ETNB
35
DELISTED
89bio
ETNB
$7.63M 0.81%
1,050,000
+50,000
+5% +$437K
PFE icon
36
Pfizer
PFE
$152B
$7.6M 0.81%
+300,000
New +$7.85M
ACHC icon
37
Acadia Healthcare
ACHC
$2.9B
$7.58M 0.81%
250,000
-50,000
-17% -$1.91M
MASI
38
DELISTED
Masimo
MASI
$7.5M 0.8%
+45,000
New +$7.81M
WAT icon
39
Waters Corp
WAT
$40.7B
$7.37M 0.78%
20,000
-10,000
-33% -$3.87M
VRNA
40
DELISTED
Verona Pharma
VRNA
$7.3M 0.78%
+115,000
New +$6.88M
DXCM icon
41
DexCom
DXCM
$33.8B
$6.83M 0.73%
100,000
-50,000
-33% -$4.08M
XENE icon
42
PUT
Xenon Pharmaceuticals
XENE
$6.11B
$6.71M 0.71%
+200,000
New +$7.59M
RGNX icon
43
Regenxbio
RGNX
$703M
$6.61M 0.7%
925,000
+25,000
+3% +$186K
EWTX icon
44
CALL
Edgewise Therapeutics
EWTX
$4.81B
$6.6M 0.7%
300,000
– –
BMY icon
45
Bristol-Myers Squibb
BMY
$130B
$6.1M 0.65%
100,000
-250,000
-71% -$14.6M
ROIV icon
46
Roivant Sciences
ROIV
$25.5B
$6.05M 0.64%
+600,000
New +$6.49M
TARA icon
47
Protara Therapeutics
TARA
$220M
$5.96M 0.63%
1,400,000
– –
RNAM
48
PUT
DELISTED
Avidity Biosciences
RNAM
$5.9M 0.63%
+200,000
New +$6.23M
IQV icon
49
IQVIA
IQV
$40.1B
$5.29M 0.56%
+30,000
New +$5.82M
CRSP icon
50
CRISPR Therapeutics
CRSP
$5.23B
$5.1M 0.54%
+150,000
New +$6.36M
1
2
3 4 5

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Integral Health Asset Management held 113 positions worth $940M, down 20% from $1.17B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Integral Health Asset Management withdrew a net $192M in Q1 2025, closing 32 positions and reducing 25 holdings. Its most notable exit was Centene, an estimated $30.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier.

Against the trend, Integral Health Asset Management opened a new position in Novartis worth $27.9M.

  • Integral Health Asset Management's largest Q1 2025 buy was Novartis: 250,000 shares worth $27.9M.
  • Integral Health Asset Management added most to Mineralys Therapeutics in Q1 2025, an estimated $16.4M increase.
  • Integral Health Asset Management's biggest Q1 2025 reduction was CVS Health, cutting an estimated $18M.
  • Integral Health Asset Management fully exited Centene in Q1 2025, selling an estimated $30.3M.
  • Integral Health Asset Management's ten largest holdings make up 47% of its $940M portfolio in Q1 2025.
  • Integral Health Asset Management opened 30 new positions and closed 32 in Q1 2025.
  • Integral Health Asset Management's portfolio value fell 20% quarter-over-quarter to $940M.

Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.